| Medical and Health Sciences | Lifetime | 252 | US 136 | 99.99 |
| Medical and Health Sciences | 2021-2025 | 767 | US 264 | 99.83 |
| Cardiology and Cardiovascular Medicine | Lifetime | 82 | US 45 | 99.92 |
| Surgery | Lifetime | 546 | US 300 | 99.50 |
| Nephrology | Lifetime | 77 | US 44 | 99.47 |
| Family Practice | Lifetime | 18 | US 9 | 98.78 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 703 | US 373 | 97.63 |
| Nutrition and Dietetics | Lifetime | 605 | US 248 | 97.26 |
| Geriatrics and Gerontology | Lifetime | 394 | US 155 | 88.54 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 111 | US 56 | 99.45 |
| Surgery | 2021-2025 | 499 | US 193 | 95.98 |
| Public, Environmental and Occupational Health | 2021-2025 | 549 | US 208 | 94.73 |
| Blood Pressure and Hypertension Studies | Lifetime | 10 | US 5 | 99.92 |
| Medication Adherence and Compliance | Lifetime | 4 | US 4 | 99.76 |
| Cardiovascular Health and Disease Prevention | Lifetime | 38 | US 16 | 99.69 |
| Heart Rate Variability and Autonomic Control | Lifetime | 66 | US 29 | 99.60 |
| Sodium Intake and Health | Lifetime | 10 | US 6 | 99.75 |
| Cardiovascular Health and Risk Factors | Lifetime | 19 | US 14 | 99.51 |
| Chronic Kidney Disease and Diabetes | Lifetime | 34 | US 19 | 99.72 |
| Pharmaceutical Practices and Patient Outcomes | Lifetime | 43 | US 21 | 99.25 |
| Dialysis and Renal Disease Management | Lifetime | 57 | US 25 | 99.59 |
| Lipoproteins and Cardiovascular Health | Lifetime | 80 | US 49 | 99.54 |
| Renal and Vascular Pathologies | Lifetime | 70 | US 48 | 99.33 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 154 | US 74 | 99.36 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 344 | US 169 | 99.03 |
| Nutritional Studies and Diet | Lifetime | 211 | US 97 | 99.19 |
| Cardiac Health and Mental Health | Lifetime | 134 | US 83 | 98.72 |
| Hormonal Regulation and Hypertension | Lifetime | 263 | US 109 | 98.58 |
| Pharmaceutical Economics and Policy | Lifetime | 114 | US 63 | 98.01 |
| Cardiovascular Syncope and Autonomic Disorders | Lifetime | 246 | US 111 | 97.55 |
| Cancer, Lipids, and Metabolism | Lifetime | 626 | US 310 | 97.74 |
| Hemodynamic Monitoring and Therapy | Lifetime | 444 | US 172 | 97.55 |
| Acute Myocardial Infarction Research | Lifetime | 878 | US 357 | 97.45 |
| Cardiovascular Disease and Adiposity | Lifetime | 985 | US 444 | 95.58 |
| Parathyroid Disorders and Treatments | Lifetime | 917 | US 361 | 95.25 |
| Disaster Response and Management | Lifetime | 718 | US 370 | 93.64 |
| Healthcare cost, quality, practices | Lifetime | 621 | US 343 | 93.30 |
| Health Promotion and Cardiovascular Prevention | Lifetime | 462 | US 117 | 91.63 |
| Sex and Gender in Healthcare | Lifetime | 930 | US 471 | 68.24 |
| Blood Pressure and Hypertension Studies | 2021-2025 | 32 | US 13 | 99.30 |
| Sodium Intake and Health | 2021-2025 | 9 | US 5 | 98.80 |
| Nutritional Studies and Diet | 2021-2025 | 214 | US 52 | 96.81 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 131 | US 53 | 97.00 |
| Cardiovascular Health and Disease Prevention | 2021-2025 | 131 | US 38 | 94.68 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 564 | US 186 | 95.23 |
| Cardiovascular Health and Risk Factors | 2021-2025 | 132 | US 77 | 93.88 |
| Hormonal Regulation and Hypertension | 2021-2025 | 156 | US 43 | 94.46 |
| Heart Rate Variability and Autonomic Control | 2021-2025 | 339 | US 102 | 93.21 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 814 | US 183 | 85.61 |
| Hemodynamic Monitoring and Therapy | 2021-2025 | 660 | US 141 | 83.64 |
| Pharmaceutical Economics and Policy | 2021-2025 | 540 | US 184 | 79.29 |
| Health Promotion and Cardiovascular Prevention | 2021-2025 | 793 | US 132 | 49.58 |
